Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)

• Company Description    TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $0.20 Daily Weekly Monthly 20 Day Moving Average: 600,241 shares Shares Outstanding: 67.78 (millions) Market Capitalization: $13.77 (millions) Beta: 1.15 52 Week High: $2.43 52 Week Low: $0.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -41.78% -41.16% 12 Week -73.11% -73.77% Year To Date -79.68% -80.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 857-399-9500 fax: - ir@tscan.com http://www.tscan.com

• General Corporate Information    Officers Gavin MacBeath - Chief Executive Officer and Director Jason A. Amello - Chief Financial Officer Katina Dorton - Director Gabriela Gruia - Director Barbara Klencke - Director Peer Information TScan Therapeutics, Inc. (CORR.) TScan Therapeutics, Inc. (RSPI) TScan Therapeutics, Inc. (CGXP) TScan Therapeutics, Inc. (BGEN) TScan Therapeutics, Inc. (GTBP) TScan Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89854M101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 67.78 Most Recent Split Date: (:1) Beta: 1.15 Market Capitalization: $13.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.20 Price/Cash Flow: - Price / Sales: 1.94 EPS Growth vs. Year Ago Period: 17.86% vs. Previous Quarter: -4.55% Sales Growth vs. Year Ago Period: -65.83% vs. Previous Quarter: 7.03% ROE 09/30/26 - - 06/30/26 - -108.72 03/31/26 - -91.94 ROA 09/30/26 - - 06/30/26 - -54.47 03/31/26 - -50.15 Current Ratio 09/30/26 - - 06/30/26 - 3.37 03/31/26 - 6.65 Quick Ratio 09/30/26 - - 06/30/26 - 3.37 03/31/26 - 6.65 Operating Margin 09/30/26 - - 06/30/26 - -1,655.35 03/31/26 - -1,360.61 Net Margin 09/30/26 - - 06/30/26 - -1,655.35 03/31/26 - -1,360.61 Pre-Tax Margin 09/30/26 - - 06/30/26 - -1,655.35 03/31/26 - -1,360.61 Book Value 09/30/26 - - 06/30/26 - 1.02 03/31/26 - 1.61 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.31 03/31/26 - 0.34 Debt-to-Capital 09/30/26 - - 06/30/26 - 23.39 03/31/26 - 25.20

Powered by Zacks Investment Research ©